Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
April 13, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
AI Investment Boom: How Tech Giants Are Leading the Charge

"Machine Learning & Artificial Intelligence" by mikemacmarketing is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • AI scribe adoption was associated with 13 fewer minutes per day in the EHR and 16 fewer minutes on documentation — a 3% and 10% reduction respectively — according to a JAMA study covering more than 8,500 clinicians across five academic medical centers
  • Primary care providers saw the biggest gains: 25 fewer minutes in the EHR and nearly 27 fewer minutes on clinical notes daily; clinicians who used scribes in 50%+ of visits saved 21 fewer EHR minutes and 27 fewer documentation minutes
  • AI scribe adoption was linked to 0.5 additional patient visits per week and $167/month in additional evaluation and management revenue per clinician — described by researchers as a “conservative lower bound” of financial benefit that health systems can compare against implementation costs
  • The tools did not reduce after-hours EHR work, suggesting clinicians are using reclaimed time for other tasks like responding to patient messages or reviewing AI-generated notes for accuracy — a finding that limits the burnout-reduction case for scribes

What Happened?

A major new study published in JAMA provides the most rigorous large-scale evidence to date on how AI scribes affect clinical workflows. Conducted across five academic medical centers with more than 8,500 clinicians, the research found that adopting an AI scribe — which records provider-patient conversations and generates draft clinical notes — was associated with 13 fewer minutes per day in the electronic health record and 16 fewer minutes on documentation. The tools also increased weekly visit volume by 0.5 appointments per clinician, translating to $167 in additional monthly revenue. Primary care providers, female clinicians, advanced practice providers, and those who used scribes most frequently saw the largest time savings — with some primary care physicians reclaiming nearly 27 minutes daily from documentation alone.

Why It Matters?

Administrative burden — particularly time spent on EHR documentation — has become one of the leading drivers of clinician burnout, a crisis that has worsened physician shortages and contributed to rising healthcare costs. AI scribes from companies including Microsoft (Nuance), Oracle, Epic, Amazon, and Abridge have been adopted rapidly by health systems on the promise of reducing that burden, but rigorous evidence on their actual impact has been scarce. This JAMA study fills a critical gap. The 10% reduction in documentation time and 1.7% increase in visit volume suggest meaningful, if modest, productivity gains — and the $167/month revenue bump, while small, gives health systems a starting point for calculating ROI against implementation costs. The finding that after-hours EHR work did not decline complicates the burnout narrative, however, suggesting clinicians may be absorbing time savings into other administrative tasks rather than logging off earlier.

What’s Next?

The AI scribe market is expanding rapidly, with major health IT vendors racing to embed ambient documentation into existing EHR workflows. The JAMA study’s subgroup findings — that higher-frequency users and primary care clinicians benefit most — suggest that health system ROI on scribe deployment will depend heavily on implementation depth and specialty mix. Researchers note that the $167/month revenue figure is a conservative floor estimate; full financial modeling would need to account for reduced overtime, lower turnover, and patient throughput gains. Future research will need to address whether time savings compound over time as clinicians become more fluent with AI-generated notes, and whether the absence of after-hours relief eventually closes as note quality improves and review time falls.

Source: Healthcare Dive

Previous Post

Iran Still Has Thousands of Missiles — and Intelligence Says It Can Get More Out of the Ground

Next Post

Oil Could Hit $140–$150 If the Hormuz Blockade Holds, Veteran Trader Warns — and $103 Is Just the Beginning

Recommended For You

Weight-Loss Drugs Like Ozempic May Also Slow Cancer — Four New Studies Show Striking Results

by Team Lumida
15 minutes ago
Eli Lilly and Novo Nordisk Shares Plunge Amid Ozempic Vision Loss Fears

GLP-1 drugs used for diabetes and obesity are linked to reduced tumor progression, lower cancer mortality, and decreased breast cancer risk across hundreds of thousands of patients in...

Read more

GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

by Team Lumida
4 days ago
GLP-1 Weight-Loss Drugs Are Triggering Rapid Muscle Loss — and Doctors Are Sounding the Alarm

As 13 million Americans take GLP-1 drugs like Ozempic and Mounjaro, a growing body of research warns the drugs can cause up to 10% lean muscle loss —...

Read more

Hospital at Home Linked to Lower Mortality and Fewer ER Visits, JAMA Study Finds

by Team Lumida
1 week ago
dextrose hanging on stainless steel IV stand

A new JAMA Network Open study of Medicare data shows hospital-at-home programs reduce in-hospital mortality, ED visits, and ICU escalations — but adoption is concentrated in urban hospitals...

Read more

8 Evidence-Based Tips for Healthy Eating, According to the NHS

by Team Lumida
2 weeks ago
vegetable salad

From starchy carbs to salt limits, the UK's National Health Service lays out the practical fundamentals of a balanced diet — and most adults are still getting it...

Read more

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
3 weeks ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
3 weeks ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
3 weeks ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
3 weeks ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
1 month ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
1 month ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more
Next Post
Geopolitical Forces Shape Oil Market Dynamics

Oil Could Hit $140–$150 If the Hormuz Blockade Holds, Veteran Trader Warns — and $103 Is Just the Beginning

Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

The Bitcoin Leverage Stack Just Got a New Layer: Stablecoins Backed by Strategy's Preferred Shares

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI CFO Fires Back: We’re Hitting Our Plan and Facing a ‘Vertical Wall of Demand’

May 1, 2026
Why Apple’s AI Approach May Save Its Reputation

Apple’s AI Ambitions Boost ICP and FET Tokens – Key Insights for Investors

September 11, 2024
a close up of a computer board with the intel core logo on it

Intel CEO Defends Moore’s Law, Unveils New AI Chips to Rival Nvidia

June 4, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018